Clinical Trial Detail

NCT ID NCT01970865
Title A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Pfizer
Indications

non-small cell lung carcinoma

Therapies

Lorlatinib

Crizotinib

Age Groups: adult

Additional content available in CKB BOOST